Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats.


Journal

Neurotoxicity research
ISSN: 1476-3524
Titre abrégé: Neurotox Res
Pays: United States
ID NLM: 100929017

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 15 10 2018
accepted: 26 03 2019
revised: 20 03 2019
pubmed: 17 4 2019
medline: 10 1 2020
entrez: 17 4 2019
Statut: ppublish

Résumé

NBOMes are N-benzylmethoxy derivatives of the 2C family hallucinogens. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) is one of the commonly used illicit drugs. It exhibits high binding affinity for 5-HT

Identifiants

pubmed: 30989482
doi: 10.1007/s12640-019-00033-x
pii: 10.1007/s12640-019-00033-x
pmc: PMC6570696
doi:

Substances chimiques

Designer Drugs 0
Dimethoxyphenylethylamine 0
Hallucinogens 0
Serotonin 333DO1RDJY
Glutamic Acid 3KX376GY7L
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 547KGL06IP
Dopamine VTD58H1Z2X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-100

Subventions

Organisme : National Science Centre
ID : 2016/21/B/NZ7/01131
Organisme : POWR
ID : 03.02.00-00-I013/1

Références

J Comp Neurol. 1999 Jun 28;409(2):187-209
pubmed: 10379914
J Neurophysiol. 1999 Dec;82(6):2989-99
pubmed: 10601434
Psychopharmacol Commun. 1975;1(6):619-29
pubmed: 1063421
Neuropharmacology. 2000;39(1):123-32
pubmed: 10665825
Brain Res. 2001 Jan 5;888(1):51-59
pubmed: 11146051
Behav Pharmacol. 1995 Dec;6(8):839-842
pubmed: 11224388
Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):643-52
pubmed: 11509227
J Neurosci. 2001 Dec 15;21(24):9856-66
pubmed: 11739593
Neuroscience. 2002;111(1):163-76
pubmed: 11955720
Brain Res. 2003 Jan 3;959(1):58-67
pubmed: 12480158
Neurosci Lett. 2003 Aug 7;346(3):137-40
pubmed: 12853103
Cereb Cortex. 2003 Aug;13(8):870-82
pubmed: 12853374
Psychopharmacologia. 1962 Mar 12;3:1-14
pubmed: 14007904
Pharmacol Ther. 2004 Feb;101(2):131-81
pubmed: 14761703
Cereb Cortex. 2004 Oct;14(10):1100-9
pubmed: 15115744
Brain Res. 2004 Oct 8;1023(1):134-40
pubmed: 15364028
Mol Pharmacol. 2006 Dec;70(6):1956-64
pubmed: 17000863
Eur J Pharmacol. 2007 Mar 22;559(2-3):132-7
pubmed: 17223101
Neuroscience. 2007 Jun 8;146(4):1677-88
pubmed: 17467185
Prog Brain Res. 2008;172:7-44
pubmed: 18772026
Neuropsychopharmacology. 2009 Jul;34(8):1958-67
pubmed: 19322172
J Neural Transm (Vienna). 2009 Dec;116(12):1591-9
pubmed: 19756361
Psychopharmacology (Berl). 2010 Apr;209(2):163-74
pubmed: 20165943
J Pharmacol Exp Ther. 2010 Dec;335(3):728-34
pubmed: 20858706
Neuropharmacology. 2011 Sep;61(3):364-81
pubmed: 21256140
Psychopharmacology (Berl). 1990;100(3):417-25
pubmed: 2138338
J Chem Neuroanat. 2011 Jul;41(4):247-55
pubmed: 21550397
Clin Toxicol (Phila). 2011 Oct;49(8):705-19
pubmed: 21970769
Forensic Sci Int. 2013 Apr 10;227(1-3):7-14
pubmed: 22989597
Clin Toxicol (Phila). 2013 Mar;51(3):174-7
pubmed: 23473462
Front Integr Neurosci. 2013 Apr 19;7:25
pubmed: 23626526
Neuropharmacology. 2014 Feb;77:200-7
pubmed: 24012658
Am J Forensic Med Pathol. 2014 Mar;35(1):20-5
pubmed: 24457586
Drug Chem Toxicol. 2015 Jan;38(1):113-9
pubmed: 24785196
Behav Brain Res. 2015 Jan 15;277:99-120
pubmed: 25036425
Psychopharmacology (Berl). 1989;97(1):118-22
pubmed: 2540505
ACS Chem Neurosci. 2015 Jul 15;6(7):1165-75
pubmed: 25547199
Psychosomatics. 2015 Mar-Apr;56(2):129-39
pubmed: 25659919
Forensic Sci Int. 2015 Apr;249:e15-8
pubmed: 25747271
Forensic Sci Int. 2015 Jun;251:e1-8
pubmed: 25841303
Neuropharmacology. 2015 Dec;99:546-53
pubmed: 26318099
J Anal Toxicol. 2015 Oct;39(8):602-6
pubmed: 26378133
J Anal Toxicol. 2015 Oct;39(8):617-23
pubmed: 26378135
Eur Rev Med Pharmacol Sci. 2015 Sep;19(17):3270-81
pubmed: 26400534
Clin Toxicol (Phila). 2016;54(2):141-6
pubmed: 26621342
Pharmacol Rev. 2016 Apr;68(2):264-355
pubmed: 26841800
Neurotox Res. 2016 Nov;30(4):606-619
pubmed: 27461536
Curr Top Behav Neurosci. 2017;32:93-117
pubmed: 27830575
Curr Top Behav Neurosci. 2017;32:283-311
pubmed: 28097528
Behav Pharmacol. 2017 Aug;28(5):375-385
pubmed: 28537942
Neuropharmacology. 2018 Nov;142:231-239
pubmed: 29499272
Neuropharmacology. 2018 Nov;142:240-250
pubmed: 29501528
Forensic Toxicol. 2019;37(1):45-58
pubmed: 30636982
Eur J Pharmacol. 1973 Jan;21(1):53-60
pubmed: 4709205
Psychopharmacologia. 1974 Apr 23;36(3):203-7
pubmed: 4844244
Life Sci. 1984 Dec 17;35(25):2505-11
pubmed: 6513725
J Neurosci Methods. 1995 Mar;57(1):93-9
pubmed: 7791370
Brain Res Mol Brain Res. 1994 Apr;23(1-2):163-78
pubmed: 8028479
Neuropharmacology. 1997 Apr-May;36(4-5):589-99
pubmed: 9225284
Neuropsychopharmacology. 1999 Jan;20(1):92-6
pubmed: 9885788

Auteurs

Monika Herian (M)

Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna, 31-343, Kraków, Poland.

Adam Wojtas (A)

Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna, 31-343, Kraków, Poland.

Katarzyna Kamińska (K)

Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna, 31-343, Kraków, Poland.

Paweł Świt (P)

Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna, 31-343, Kraków, Poland.

Anna Wach (A)

Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna, 31-343, Kraków, Poland.

Krystyna Gołembiowska (K)

Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna, 31-343, Kraków, Poland. nfgolemb@cyf-kr.edu.pl.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH